[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

JPWO2019144102A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019144102A5
JPWO2019144102A5 JP2020561572A JP2020561572A JPWO2019144102A5 JP WO2019144102 A5 JPWO2019144102 A5 JP WO2019144102A5 JP 2020561572 A JP2020561572 A JP 2020561572A JP 2020561572 A JP2020561572 A JP 2020561572A JP WO2019144102 A5 JPWO2019144102 A5 JP WO2019144102A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
e4orf1
sci
administered
npc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020561572A
Other languages
Japanese (ja)
Other versions
JP7391308B2 (en
JP2021512148A (en
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/014497 external-priority patent/WO2019144102A1/en
Publication of JP2021512148A publication Critical patent/JP2021512148A/en
Publication of JPWO2019144102A5 publication Critical patent/JPWO2019144102A5/ja
Application granted granted Critical
Publication of JP7391308B2 publication Critical patent/JP7391308B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (20)

有効量のE4ORF1+CNS由来の内皮細胞（E4ORF1+EC）および有効量の神経前駆細胞（NPC）を有効成分として含む、哺乳動物対象における脊髄損傷（SCI）の治療剤であって、SCIを有する対象にSCIの部位で局所投与し、それにより対象におけるSCIを治療し、該治療の結果、（a）脊髄損傷の部位を介した機能的軸索の成長および／または伸長、および／または（b）SCI関連の感覚または運動障害における検出可能な改善となる、SCIの治療剤。 A therapeutic agent for spinal cord injury (SCI) in mammalian subjects containing an effective amount of E4ORF1 + CNS-derived endothelial cells (E4ORF1 + EC) and an effective amount of neural progenitor cells (NPC) as active ingredients, and having SCI. Subjects are administered topically at the site of SCI, thereby treating SCI in the subject, resulting in (a) growth and / or elongation of functional axons through the site of spinal cord injury , and / or (b) . ) A therapeutic agent for SCI that provides a detectable improvement in SCI-related sensory or motor disorders. NPC神経細胞に対するE4ORF1+ECの比率が約1:1である、請求項１に記載の治療剤。 The therapeutic agent according to claim 1, wherein the ratio of E4ORF1 + EC to NPC neurons is about 1: 1. E4ORF1+ECおよびNPCを生理食塩水中で対象に投与する、請求項１に記載の治療剤。 The therapeutic agent according to claim 1, wherein E4ORF1 + EC and NPC are administered to a subject in physiological saline. E4ORF1+ECおよびNPCを一緒に対象に投与する、請求項１に記載の治療剤。 The therapeutic agent according to claim 1, wherein E4ORF1 + EC and NPC are administered to the subject together. E4ORF1+ECおよびNPCを別々に対象に投与する、請求項１に記載の治療剤。 The therapeutic agent according to claim 1, wherein E4ORF1 + EC and NPC are separately administered to the subject. E4ORF1+ECおよびNPCをSCI損傷の亜急性期内に対象に投与する、請求項１に記載の治療剤。 The therapeutic agent according to claim 1, wherein E4ORF1 + EC and NPC are administered to a subject within the subacute phase of SCI injury. E4ORF1+ECおよびNPCをSCIの部位への直接注射により投与する、請求項１に記載の治療剤。 The therapeutic agent according to claim 1, wherein E4ORF1 + EC and NPC are administered by direct injection to the site of SCI. E4ORF1+ECおよび/またはNPCを生体適合性マトリックス中で対象に投与する、請求項１に記載の治療剤。 The therapeutic agent of claim 1, wherein E4ORF1 + EC and / or NPCs are administered to the subject in a biocompatibility matrix. E4ORF1+ECおよび/またはNPCを固体3D生体適合性マトリックス材料中で対象に投与する、請求項１に記載の治療剤。 The therapeutic agent of claim 1, wherein E4ORF1 + EC and / or NPCs are administered to the subject in a solid 3D biocompatible matrix material. E4ORF1+ECおよび/またはNPCを生体適合性マトリックス材料中で対象に投与しない、請求項１に記載の治療剤。 The therapeutic agent of claim 1, wherein E4ORF1 + EC and / or NPCs are not administered to the subject in a biocompatible matrix material. 有効量のE4ORF1+CNS由来の内皮細胞（E4ORF1+EC）および有効量の神経前駆細胞（NPC）を含む、脊髄損傷の治療方法に使用するための医薬組成物。 A pharmaceutical composition comprising an effective amount of E4ORF1 + CNS-derived endothelial cells (E4ORF1 + EC) and an effective amount of neural progenitor cells (NPC) for use in a method of treating spinal cord injury . NPC神経細胞に対するE4ORF1+ECの比率が約1:1である、請求項１１に記載の医薬組成物。 The pharmaceutical composition according to claim 11, wherein the ratio of E4ORF1 + EC to NPC neurons is about 1: 1. 生理食塩水を含む、請求項１１に記載の医薬組成物。 The pharmaceutical composition according to claim 11, which comprises a saline solution. 生体適合性マトリックス材料を含む、請求項１１に記載の医薬組成物。 11. The pharmaceutical composition of claim 11, comprising a biocompatible matrix material. 生体適合性マトリックス材料を含まない、請求項１１に記載の医薬組成物。 The pharmaceutical composition according to claim 11, which does not contain a biocompatible matrix material. （a）E4ORF1+内皮細胞（EC）、および（b）神経細胞を有効成分として含む、対象における脊髄損傷（SCI）の治療剤であって、SCIを有する対象にSCIの部位で局所投与し、それにより対象におけるSCIを治療する、治療剤。 A therapeutic agent for spinal cord injury (SCI) in subjects containing (a) E4ORF1 + endothelial cells (EC) and (b) nerve cells as active ingredients, which are locally administered to subjects with SCI at the site of SCI . A therapeutic agent that treats SCI in a subject. ECが哺乳動物ECである、請求項１６に記載の治療剤。 The therapeutic agent according to claim 16, wherein the EC is a mammalian EC. ECがヒトECである、請求項１６に記載の治療剤。 The therapeutic agent according to claim 16, wherein the EC is a human EC. ECが、臍帯静脈EC（UVEC）、脳EC、脊髄EC、および嗅球ECよりなる群から選ばれる、請求項１６に記載の治療剤。 The therapeutic agent according to claim 16, wherein the EC is selected from the group consisting of umbilical vein EC (UVEC), brain EC, spinal cord EC, and olfactory bulb EC. 神経細胞が分化した神経細胞である、請求項１６に記載の治療剤。 The therapeutic agent according to claim 16, wherein the nerve cell is a differentiated nerve cell.
JP2020561572A 2018-01-22 2019-01-22 Compositions and methods for treating spinal cord injury Active JP7391308B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862620269P 2018-01-22 2018-01-22
US62/620,269 2018-01-22
PCT/US2019/014497 WO2019144102A1 (en) 2018-01-22 2019-01-22 Compositions and methods for treatment of spinal cord injury

Publications (3)

Publication Number Publication Date
JP2021512148A JP2021512148A (en) 2021-05-13
JPWO2019144102A5 true JPWO2019144102A5 (en) 2022-02-24
JP7391308B2 JP7391308B2 (en) 2023-12-05

Family

ID=67301897

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020561572A Active JP7391308B2 (en) 2018-01-22 2019-01-22 Compositions and methods for treating spinal cord injury

Country Status (7)

Country Link
US (1) US20210030810A1 (en)
EP (1) EP3743085A4 (en)
JP (1) JP7391308B2 (en)
CN (1) CN111886016A (en)
AU (1) AU2019209439A1 (en)
CA (1) CA3089324A1 (en)
WO (1) WO2019144102A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL265352B2 (en) 2016-09-13 2024-05-01 Angiocrine Bioscience Inc Blood-brain barrier comprising engineered endothelial cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8465732B2 (en) * 2007-01-19 2013-06-18 Cornell Research Foundation, Inc. Endothelial cells expressing adenovirus E4ORF1 and methods of use thereof
JP6889107B2 (en) 2014-06-27 2021-06-18 アンジオクライン・バイオサイエンス・インコーポレイテッドＡｎｇｉｏｃｒｉｎｅ Ｂｉｏｓｃｉｅｎｃｅ， Ｉｎｃ． Nervous system cells expressing adenovirus E4ORF1, and methods for producing and using them.
KR101675123B1 (en) * 2014-06-27 2016-11-14 연세대학교 산학협력단 A Composition for Treating Ischemic Diseases or Neuroinflammatory Diseases Comprising PSA-NCAM-positive Neural Precursor Cells as Active Ingredient
AU2016283612B2 (en) 2015-06-26 2019-01-24 S-Biomedics Composition for treating ischemic diseases or neuroinflammatory diseases, comprising secretome of neural precursor cells as active ingredient
US10961509B2 (en) 2015-07-20 2021-03-30 Angiocrine Bioscience, Inc. Engineered endothelial cells expressing an ETS transcription factor

Similar Documents

Publication Publication Date Title
Bennett et al. Spastic long-lasting reflexes in the awake rat after sacral spinal cord injury
US11905510B2 (en) Methods and systems for activating cells to treat aging
Grossman Effects of stimulation of non-specific thalamic system on locomotor movements in cat
CN107072716A (en) Methods and systems for generating and using activated stem cells
RU2558294C1 (en) Codon-optimised recombinant plasmid, stimulation technique for peripheral nerve regeneration, treatment modality for damaged human nerve
EP3373996B1 (en) Method for generation, use and delivery of activated stem cells
Mallory et al. Optical stimulation for restoration of motor function after spinal cord injury
JPWO2019144102A5 (en)
JP2022502379A (en) Amino acid derivatives of glucosamine that promote the synthesis of extracellular matrix, and pharmaceutical compositions containing them.
JP2009504636A (en) Pharmaceutical composition for treatment of nerve injury comprising plasma or serum
EP4248982A1 (en) Anti-aging regeneration composition
Juffe et al. Cardialization a new source of energy for circulatory assistance
Manni et al. Mesodiencephalic representation of the eye muscle proprioception
US5981508A (en) Facilitation of repair of neural injury with CM101/GBS toxin
US20220023623A1 (en) Sonic hedgehog delivery
RU2666942C1 (en) Method for treatment polyneiromyopathy of critical conditions in resanimatory patients
RU2120289C1 (en) Method for treating the cases of neurologic manifestations of osteochondrosis
RU2778425C2 (en) Method and system for generation and use of activated stem cells
US20210008102A1 (en) Regenerative co2 treatment apparatus and method
RU2462280C1 (en) Method for cytoflavin electric accumulation in treating vascular and dystrophic retinal and visual nerve diseases
Wang et al. Liquid metal enabled electrobiology: A generalized easy going way to tackle disease challenges
JP2000500999A (en) Device for enhanced release of biologically active substances and compounds into living organisms
Jain et al. Biotechnology in Neuroregeneration
McCrea Activity of spinal neurons during controlled locomotion
Keyzer et al. THE APPLICATION OF ELECTROPHARMACOLOGY TO BONE